Medivir (MVIR) Stock Overview
A pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MVIR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.68 |
| 52 Week High | SEK 2.89 |
| 52 Week Low | SEK 0.34 |
| Beta | 0.11 |
| 1 Month Change | -16.11% |
| 3 Month Change | -26.23% |
| 1 Year Change | 1.94% |
| 3 Year Change | -76.46% |
| 5 Year Change | -79.78% |
| Change since IPO | -98.74% |
Recent News & Updates
MVIR: Future Equity Raises And Liver Cancer Data Will Drive Repricing
Analysts now estimate Medivir's fair value increasing from about SEK2.50 to roughly SEK5.47 per share, citing updated assumptions around revenue growth, margins and future P/E levels. What’s in the News for Medivir Medivir has completed a follow on equity offering of approximately SEK140.0 million in ordinary shares, with 85,365,854 securities offered at SEK1.64 per share, via a subsequent direct listing.We're Hopeful That Medivir (STO:MVIR) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Recent updates
MVIR: Future Equity Raises And Liver Cancer Data Will Drive Repricing
Analysts now estimate Medivir's fair value increasing from about SEK2.50 to roughly SEK5.47 per share, citing updated assumptions around revenue growth, margins and future P/E levels. What’s in the News for Medivir Medivir has completed a follow on equity offering of approximately SEK140.0 million in ordinary shares, with 85,365,854 securities offered at SEK1.64 per share, via a subsequent direct listing.We're Hopeful That Medivir (STO:MVIR) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects
Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story
Catalysts About Medivir Medivir is a research based pharmaceutical company focused on developing first in class therapies for oncology and rare bone disorders. What are the underlying business or industry changes driving this perspective?Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Shareholder Returns
| MVIR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.7% | 4.2% | -0.8% |
| 1Y | 1.9% | 28.5% | 10.3% |
Return vs Industry: MVIR underperformed the Swedish Biotechs industry which returned 32.4% over the past year.
Return vs Market: MVIR underperformed the Swedish Market which returned 13.5% over the past year.
Price Volatility
| MVIR volatility | |
|---|---|
| MVIR Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: MVIR's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MVIR's weekly volatility has decreased from 21% to 10% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 7 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection.
Medivir AB (publ) Fundamentals Summary
| MVIR fundamental statistics | |
|---|---|
| Market cap | SEK 1.04b |
| Earnings (TTM) | -SEK 90.50m |
| Revenue (TTM) | SEK 9.01m |
Is MVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVIR income statement (TTM) | |
|---|---|
| Revenue | SEK 9.01m |
| Cost of Revenue | SEK 39.81m |
| Gross Profit | -SEK 30.81m |
| Other Expenses | SEK 59.69m |
| Earnings | -SEK 90.50m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | -0.15 |
| Gross Margin | -342.08% |
| Net Profit Margin | -1,004.89% |
| Debt/Equity Ratio | 0% |
How did MVIR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 23:44 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medivir AB (publ) is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |
| Klas Palin | DNB Carnegie Commissioned Research |